FORE Biotherapeutics Announces Positive Outcome From a Planned Interim Efficacy Analysis for the FORTE Basket Study Evaluating Plixorafenib as a Monotherapy for Recurrent or Progressive BRAF V600 Primary CNS Tumors

businesswire

FORE Biotherapeutics Announces Positive Outcome From a Planned Interim Efficacy Analysis for the FORTE Basket Study Evaluating Plixorafenib as a Monotherapy for Recurrent or Progressive BRAF V600 Primary CNS Tumors – NEWSnet – News… as it used to be

More Press Releases

Featured image for Auto-prepared featured image

June 10, 2026

RN MEDFLIGHTS Offers Licensed Nurse Escorts, Saving Families $30K–$80K vs. Air Ambulance

June 10, 2026

Dangerous New World Screwworm Spreading Across County And State Borders While International Borders Close

June 10, 2026

/C O R R E C T I O N — O Positiv Health/

June 10, 2026

FORE Biotherapeutics Announces Positive Outcome From a Planned Interim Efficacy Analysis for the FORTE Basket Study Evaluating Plixorafenib as a Monotherapy for Recurrent or Progressive BRAF V600 Primary CNS Tumors

RN MEDFLIGHTS Offers Licensed Nurse Escorts, Saving Families $30K–$80K vs. Air Ambulance

Dangerous New World Screwworm Spreading Across County And State Borders While International Borders Close

/C O R R E C T I O N — O Positiv Health/

Drone Logistics Market to Reach USD 53.32 Billion by 2031 from USD 8.20 Billion in 2021, Growing at 20.8% CAGR